Introduction: Antibody Structure and Function

Therapeutic Fc-Fusion Proteins

Volumn , Issue , 2013, Pages 1-43

  Rajpal, Arvind ^a   Strop, Pavel ^a   Yeung, Yik Andy ^a   Chaparro Riggers, Javier ^a   Pons, Jaume ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019826379     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527675272.ch01     Document Type: Editorial

References (226)

1. Ehrlich, P. (1880) Methodologische Beitrage zur Physiologie und Pathologie der verschiedenen Formen der Leukocyten. Z. Klin. Med., 1, 553.
2. Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256 (5517), 495-497.
3. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy. Nature, 332 (6162), 323-327.
4. Giudicelli, V., Chaume, D., and Lefranc, M.P. (2005) IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res., 33 (Database issue), D256-D261.
5. RCSB (2013) Protein Data Bank. Available at http://www.rcsb.org/pdb/home/home. do (accessed July 15, 2013).
6. Saphire, E.O., Stanfield, R.L., Crispin, M.D., Parren, P.W., Rudd, P.M., Dwek, R.A., Burton, D.R., and Wilson, I.A. (2002) Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol., 319 (1), 9-18.
7. Radaev, S., Motyka, S., Fridman, W.H., Sautes-Fridman, C., and Sun, P.D. (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem., 276 (19), 16469-16477.
8. Ramsland, P.A., Farrugia, W., Bradford, T.M., Sardjono, C.T., Esparon, S., Trist, H.M., Powell, M.S., Tan, P.S., Cendron, A.C., Wines, B.D., Scott, A.M., and Hogarth, P.M. (2011) Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol., 187 (6), 3208-3217.
9. Burmeister, W.P., Gastinel, L.N., Simister, N.E., Blum, M.L., and Bjorkman, P.J. (1994) Crystal structure at 2.2A' resolution of the MHC-related neonatal Fc receptor. Nature, 372 (6504), 336-343.
10. Deisenhofer, J. (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A' resolution. Biochemistry, 20 (9), 2361-2370.
11. Shivhare, M. and McCreath, G. (2010) Practical considerations for DoE implementation in quality by design. BioProcess Int., 8 (6), 22-30.
12. Wu, T.T. and Kabat, E.A. (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med., 132 (2), 211-250.
13. Chothia, C. and Lesk, A.M. (1987) Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol., 196 (4), 901-917.
14. Kabat, E.A. (1991) Sequences of Proteins of Immunological Interest: Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptors for Antigen T-Cell Surface Antigens, [Beta]2-Microglobulins, Major Histocompatibility Antigens, Thy-1, Complement, C-Reactive Protein, Thymopoietin, Integrins, Post-Gamma Globulin, [Alpha]2-Macroglobulins, and Other Related Proteins, 5th edn, National Institutes of Health.
15. Lonberg, N. (2005) Human antibodies from transgenic animals. Nat. Biotechnol., 23 (9), 1117-1125.
16. Yu, X., Tsibane, T., McGraw, P.A., House, F.S., Keefer, C.J., Hicar, M.D., Tumpey, T.M., Pappas, C., Perrone, L.A., Martinez, O., Stevens, J., Wilson, I.A., Aguilar, P.V., Altschuler, E.L., Basler, C.F., and Crowe, J.E., Jr. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature, 455 (7212), 532-536.
17. Vaughan, T.J., Williams, A.J., Pritchard, K., Osbourn, J.K., Pope, A.R., Earnshaw, J.C., McCafferty, J., Hodits, R.A., Wilton, J., and Johnson, K.S. (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol., 14 (3), 309-314.
18. Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., and Virnekas, B. (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol., 296 (1), 57-86.
19. Zhai, W., Glanville, J., Fuhrmann, M., Mei, L., Ni, I., Sundar, P.D., Van Blarcom, T., Abdiche, Y., Lindquist, K., Strohner, R., Telman, D., Cappuccilli, G., Finlay, W.J., Van den Brulle, J., Cox, D.R., Pons, J., and Rajpal, A. (2011) Synthetic antibodies designed on natural sequence landscapes. J. Mol. Biol., 412 (1), 55-71.
20. Nimmerjahn, F. and Ravetch, J.V. (2008) Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol., 8 (1), 34-47.
21. Martin, W.L., West, A.P., Jr., Gan, L., and Bjorkman, P.J. (2001) Crystal structure at 2.8A' of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell, 7 (4), 867-877.
22. Roopenian, D.C. and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 7 (9), 715-725.
23. Ghetie, V. and Ward, E.S. (2000) Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol., 18, 739-766.
24. Sauer-Eriksson, A.E., Kleywegt, G.J., Uhlen, M., and Jones, T.A. (1995) Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure, 3 (3), 265-278.
25. Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) The 3.2-A' crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature, 406 (6793), 267-273.
26. Sondermann, P., Kaiser, J., and Jacob, U. (2001) Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol., 309 (3), 737-749.
27. Nimmerjahn, F. and Ravetch, J.V. (2008) Analyzing antibody-Fc-receptor interactions. Methods Mol. Biol., 415, 151-162.
28. Schneider, S. and Zacharias, M. (2012) Atomic resolution model of the antibody Fc interaction with the complement C1q component. Mol. Immunol., 51 (1), 66-72.
29. Ferrara, C., Grau, S., Jager, C., Sondermann, P., Brunker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A.C., Stihle, M., Umana, P., and Benz, J. (2011) Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA, 108 (31), 12669-12674.
30. Zheng, K., Bantog, C., and Bayer, R. (2011) The impact of glycosylation on monoclonal antibody conformation and stability. mAbs, 3 (6), 568-576.
31. Jefferis, R., Lund, J., Mizutani, H., Nakagawa, H., Kawazoe, Y., Arata, Y., and Takahashi, N. (1990) A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J., 268 (3), 529-537.
32. Hansen, R., Dickson, A.J., Goodacre, R., Stephens, G.M., and Sellick, C.A. (2010) Rapid characterization of N-linked glycans from secreted and gel-purified monoclonal antibodies using MALDI-ToF mass spectrometry. Biotechnol. Bioeng., 107 (5), 902-908.
33. Sheeley, D.M., Merrill, B.M., and Taylor, L.C. (1997) Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. Anal. Biochem., 247 (1), 102-110.
34. Lund, J., Takahashi, N., Pound, J.D., Goodall, M., Nakagawa, H., and Jefferis, R. (1995) Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors. FASEB J., 9 (1), 115-119.
35. Tao, M.H. and Morrison, S.L. (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol., 143 (8), 2595-2601.
36. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H., and Presta, L.G. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem., 277 (30), 26733-26740.
37. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., and Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J. Biol. Chem., 278 (5), 3466-3473.
38. Kaneko, Y., Nimmerjahn, F., and Ravetch, J.V. (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313 (5787), 670-673.
39. Aalberse, R.C. and Schuurman, J. (2002) IgG4 breaking the rules. Immunology, 105 (1), 9-19.
40. Labrijn, A.F., Buijsse, A.O., van den Bremer, E.T., Verwilligen, A.Y., Bleeker, W.K., Thorpe, S.J., Killestein, J., Polman, C.H., Aalberse, R.C., Schuurman, J., van de Winkel, J.G., and Parren, P.W. (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol., 27 (8), 767-771.
41. Stein, T.P., Leskiw, M.J., and Wallace, H.W. (1978) Measurement of half-life human plasma fibrinogen. Am. J. Physiol., 234 (5), D504-D510.
42. Rogentine, G.N., Jr., Rowe, D.S., Bradley, J., Waldmann, T.A., and Fahey, J.L. (1966) Metabolism of human immunoglobulin D (IgD). J. Clin. Invest., 45 (9), 1467-1478.
43. Barth, W.F., Wochner, R.D., Waldmann, T.A., and Fahey, J.L. (1964) Metabolism of human gamma macroglobulins. J. Clin. Invest., 43, 1036-1048.
44. Strober, W., Wochner, R.D., Barlow, M.H., McFarlin, D.E., andWaldmann, T.A. (1968) Immunoglobulin metabolism in ataxia telangiectasia. J. Clin. Invest., 47 (8), 1905-1915.
45. Anderson, C.L., Chaudhury, C., Kim, J., Bronson, C.L., Wani, M.A., and Mohanty, S. (2006) Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol., 27 (7), 343-348.
46. He, W., Ladinsky, M.S., Huey-Tubman, K.E., Jensen, G.J., McIntosh, J.R., and Bjorkman, P.J. (2008) FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature, 455 (7212), 542-546.
47. Hinton, P.R., Johlfs, M.G., Xiong, J.M., Hanestad, K., Ong, K.C., Bullock, C., Keller, S., Tang, M.T., Tso, J.Y., Vasquez, M., and Tsurushita, N. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem., 279 (8), 6213-6216.
48. Dall'Acqua, W.F., Kiener, P.A., and Wu, H. (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem., 281 (33), 23514-23524.
49. Hinton, P.R., Xiong, J.M., Johlfs, M.G., Tang, M.T., Keller, S., and Tsurushita, N. (2006) An engineered human IgG1 antibody with longer serum half-life. J. Immunol., 176 (1), 346-356.
50. Datta-Mannan, A., Witcher, D.R., Tang, Y., Watkins, J., Jiang, W., and Wroblewski, V.J. (2007) Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos., 35 (1), 86-94.
51. Datta-Mannan, A., Witcher, D.R., Tang, Y., Watkins, J., and Wroblewski, V.J. (2007) Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J. Biol. Chem., 282 (3), 1709-1717.
52. Yeung, Y.A., Leabman, M.K., Marvin, J.S., Qiu, J., Adams, C.W., Lien, S., Starovasnik, M.A., and Lowman, H.B. (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J. Immunol., 182 (12), 7663-7671.
53. Zalevsky, J., Chamberlain, A.K., Horton, H.M., Karki, S., Leung, I.W., Sproule, T.J., Lazar, G.A., Roopenian, D.C., and Desjarlais, J.R. (2010) Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol., 28 (2), 157-159.
54. Yeung, Y.A., Wu, X., Reyes, A.E., 2nd, Vernes, J.M., Lien, S., Lowe, J., Maia, M., Forrest, W.F., Meng, Y.G., Damico, L.A., Ferrara, N., and Lowman, H.B. (2010) A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res., 70 (8), 3269-3277.
55. Zheng, Y., Scheerens, H., Davis, J.C., Jr., Deng, R., Fischer, S.K., Woods, C., Fielder, P.J., and Stefanich, E.G. (2011) Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin. Pharmacol. Ther., 89 (2), 283-290.
56. Datta-Mannan, A., Chow, C.K., Dickinson, C., Driver, D., Lu, J., Witcher, D.R., and Wroblewski, V.J. (2012) FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab. Dispos., 40 (8), 1545-1555.
57. Brambell, F.W., Halliday, R., and Morris, I.G. (1958) Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice. Proc. R. Soc. Lond. B Biol. Sci., 149 (934), 1-11.
58. Simister, N.E. and Mostov, K.E. (1989) An Fc receptor structurally related to MHC class I antigens. Nature, 337 (6203), 184-187.
59. Brambell, F.W., Hemmings, W.A., and Morris, I.G. (1964) A theoretical model of gamma-globulin catabolism. Nature, 203, 1352-1354.
60. Ghetie, V., Hubbard, J.G., Kim, J.K., Tsen, M.F., Lee, Y., and Ward, E.S. (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol., 26 (3), 690-696.
61. Wani, M.A., Haynes, L.D., Kim, J., Bronson, C.L., Chaudhury, C., Mohanty, S., Waldmann, T.A., Robinson, J.M., and Anderson, C.L. (2006) Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc. Natl. Acad. Sci. USA, 103 (13), 5084-5089.
62. Tzaban, S., Massol, R.H., Yen, E., Hamman, W., Frank, S.R., Lapierre, L.A., Hansen, S.H., Goldenring, J.R., Blumberg, R.S., and Lencer, W.I. (2009) The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J. Cell Biol., 185 (4), 673-684.
63. Vidarsson, G., Stemerding, A.M., Stapleton, N.M., Spliethoff, S.E., Janssen, H., Rebers, F.E., de Haas, M., and van de Winkel, J.G. (2006) FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood, 108 (10), 3573-3579.
64. Ye, L., Zeng, R., Bai, Y., Roopenian, D.C., and Zhu, X. (2011) Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat. Biotechnol., 29 (2), 158-163.
65. Qiao, S.W., Kobayashi, K., Johansen, F.E., Sollid, L.M., Andersen, J.T., Milford, E., Roopenian, D.C., Lencer, W.I., and Blumberg, R.S. (2008) Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. USA, 105 (27), 9337-9342.
66. Baker, K., Qiao, S.W., Kuo, T.T., Aveson, V.G., Platzer, B., Andersen, J.T., Sandlie, I., Chen, Z., de Haar, C., Lencer, W.I., Fiebiger, E., and Blumberg, R.S. (2011) Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11bþ dendritic cells. Proc. Natl. Acad. Sci. USA, 108 (24), 9927-9932.
67. West, A.P., Jr. and Bjorkman, P.J. (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry, 39 (32), 9698-9708.
68. Sanchez, L.M., Penny, D.M., and Bjorkman, P.J. (1999) Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry, 38 (29), 9471-9476.
69. Tesar, D.B., Tiangco, N.E., and Bjorkman, P.J. (2006) Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic, 7 (9), 1127-1142.
70. Burmeister, W.P., Huber, A.H., and Bjorkman, P.J. (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 372 (6504), 379-383.
71. Kim, J.K., Firan, M., Radu, C.G., Kim, C.H., Ghetie, V., and Ward, E.S. (1999) Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol., 29 (9), 2819-2825.
72. Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J.A., and Presta, L.G. (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem., 276 (9), 6591-6604.
73. Zhou, J., Johnson, J.E., Ghetie, V., Ober, R.J., and Ward, E.S. (2003) Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J. Mol. Biol., 332 (4), 901-913.
74. Zhou, J., Mateos, F., Ober, R.J., and Ward, E.S. (2005) Conferring the binding properties of the mouse MHC class Irelated receptor, FcRn, onto the human ortholog by sequential rounds of sitedirected mutagenesis. J. Mol. Biol., 345 (5), 1071-1081.
75. Andersen, J.T., Dee Qian, J., and Sandlie, I. (2006) The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur. J. Immunol., 36 (11), 3044-3051.
76. Raghavan, M., Bonagura, V.R., Morrison, S.L., and Bjorkman, P.J. (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry, 34 (45), 14649-14657.
77. Ober, R.J., Martinez, C., Vaccaro, C., Zhou, J., and Ward, E.S. (2004) Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J. Immunol., 172 (4), 2021-2029.
78. Prabhat, P., Gan, Z., Chao, J., Ram, S., Vaccaro, C., Gibbons, S., Ober, R.J., and Ward, E.S. (2007) Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc. Natl. Acad. Sci. USA, 104 (14), 5889-5894.
79. Ober, R.J., Martinez, C., Lai, X., Zhou, J., and Ward, E.S. (2004) Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl. Acad. Sci. USA, 101 (30), 11076-11081.
80. Borvak, J., Richardson, J., Medesan, C., Antohe, F., Radu, C., Simionescu, M., Ghetie, V., and Ward, E.S. (1998) Functional expression of the MHC class Irelated receptor, FcRn, in endothelial cells of mice. Int. Immunol., 10 (9), 1289-1298.
81. Zhu, X., Meng, G., Dickinson, B.L., Li, X., Mizoguchi, E., Miao, L., Wang, Y., Robert, C., Wu, B., Smith, P.D., Lencer, W.I., and Blumberg, R.S. (2001) MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J. Immunol., 166 (5), 3266-3276.
82. Dickinson, B.L., Badizadegan, K., Wu, Z., Ahouse, J.C., Zhu, X., Simister, N.E., Blumberg, R.S., and Lencer, W.I. (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J. Clin. Invest., 104 (7), 903-911.
83. Schlachetzki, F., Zhu, C., and Pardridge, W.M. (2002) Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem., 81 (1), 203-206.
84. Deane, R., Sagare, A., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D.M., and Zlokovic, B.V. (2005) IgGassisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci., 25 (50), 11495-11503.
85. Akilesh, S., Huber, T.B., Wu, H., Wang, G., Hartleben, B., Kopp, J.B., Miner, J.H., Roopenian, D.C., Unanue, E.R., and Shaw, A.S. (2008) Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc. Natl. Acad. Sci. USA, 105 (3), 967-972.
86. Antohe, F., Radulescu, L., Gafencu, A., Ghetie, V., and Simionescu, M. (2001) Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum. Immunol., 62 (2), 93-105.
87. Simister, N.E. (2003) Placental transport of immunoglobulin G. Vaccine, 21 (24), 3365-3369.
88. Spiekermann, G.M., Finn, P.W., Ward, E.S., Dumont, J., Dickinson, B.L., Blumberg, R.S., and Lencer, W.I. (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med., 196 (3), 303-310.
89. Akilesh, S., Christianson, G.J., Roopenian, D.C., and Shaw, A.S. (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol., 179 (7), 4580-4588.
90. Montoyo, H.P., Vaccaro, C., Hafner, M., Ober, R.J., Mueller, W., and Ward, E.S. (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. USA, 106 (8), 2788-2793.
91. UniProt (2013) Protein Knowledgebase. Available at www. uniprot.org/ (accessed June 21, 2013).
92. Mayer, B., Zolnai, A., Frenyo, L.V., Jancsik, V., Szentirmay, Z., Hammarstrom, L., and Kacskovics, I. (2002) Localization of the sheep FcRn in the mammary gland. Vet. Immunol. Immunopathol., 87 (3-4), 327-330.
93. Leach, J.L., Sedmak, D.D., Osborne, J.M., Rahill, B., Lairmore, M.D., and Anderson, C.L. (1996) Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J. Immunol., 157 (8), 3317-3322.
94. Kacskovics, I., Kis, Z., Mayer, B., West, A.P., Jr., Tiangco, N.E., Tilahun, M., Cervenak, L., Bjorkman, P.J., Goldsby, R.A., Szenci, O., and Hammarstrom, L. (2006) FcRn mediates elongated serum half-life of human IgG in cattle. Int. Immunol., 18 (4), 525-536.
95. Zheng, Y., Tesar, D.B., Benincosa, L., Birnbock, H., Boswell, C.A., Bumbaca, D., Cowan, K.J., Danilenko, D.M., Daugherty, A.L., Fielder, P.J., Grimm, H.P., Joshi, A., Justies, N., Kolaitis, G., Lewin-Koh, N., Li, J., McVay, S., O'Mahony, J., Otteneder, M., Pantze, M., Putnam, W.S., Qiu, Z.J., Ruppel, J., Singer, T., Stauch, O., Theil, F.P., Visich, J., Yang, J., Ying, Y., Khawli, L.A., and Richter, W.F. (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs, 4 (2), 243-255.
96. West, A.P., Jr., Herr, A.B., and Bjorkman, P.J. (2004) The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity, 20 (5), 601-610.
97. Ober, R.J., Radu, C.G., Ghetie, V., and Ward, E.S. (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol., 13 (12), 1551-1559.
98. Andersen, J.T., Pehrson, R., Tolmachev, V., Daba, M.B., Abrahmsen, L., and Ekblad, C. (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem., 286 (7), 5234-5241.
99. Olafsen, T., Kenanova, V.E., and Wu, A.M. (2006) Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc., 1 (4), 2048-2060.
100. Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R.J., and Ward, E.S. (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol., 15 (7), 637-640.
101. Petkova, S.B., Akilesh, S., Sproule, T.J., Christianson, G.J., Al Khabbaz, H., Brown, A.C., Presta, L.G., Meng, Y.G., and Roopenian, D.C. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol., 18 (12), 1759-1769.
102. Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R.J., and Ward, E.S. (2006) Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc. Natl. Acad. Sci. USA, 103 (49), 18709-18714.
103. Kuo, T.T., de Muinck, E.J., Claypool, S.M., Yoshida, M., Nagaishi, T., Aveson, V.G., Lencer, W.I., and Blumberg, R.S. (2009) NGlycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. J. Biol. Chem., 284 (13), 8292-8300.
104. Andersen, J.T., Foss, S., Kenanova, V.E., Olafsen, T., Leikfoss, I.S., Roopenian, D.C., Wu, A.M., and Sandlie, I. (2012) Anticarcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum halflife. J. Biol. Chem., 287 (27), 22927-22937.
105. Vaccaro, C., Zhou, J., Ober, R.J., and Ward, E.S. (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol., 23 (10), 1283-1288.
106. Nakano, K., Ishiguro, T., Konishi, H., Tanaka, M., Sugimoto, M., Sugo, I., Igawa, T., Tsunoda, H., Kinoshita, Y., Habu, K., Orita, T., Tsuchiya, M., Hattori, K., and Yamada-Okabe, H. (2010) Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs, 21 (10), 907-916.
107. Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., and Hattori, K. (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng. Des. Sel., 23 (5), 385-392.
108. Igawa, T., Tsunoda, H., Kikuchi, Y., Yoshida, M., Tanaka, M., Koga, A., Sekimori, Y., Orita, T., Aso, Y., Hattori, K., and Tsuchiya, M. (2010) VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng. Des. Sel., 23 (8), 667-677.
109. Chaparro-Riggers, J., Liang, H., DeVay, R.M., Bai, L., Sutton, J.E., Chen, W., Geng, T., Lindquist, K., Casas, M.G., Boustany, L.M., Brown, C.L., Chabot, J., Gomes, B., Garzone, P., Rossi, A., Strop, P., Shelton, D., Pons, J., and Rajpal, A. (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J. Biol. Chem., 287 (14), 11090-11097.
110. Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., Wakabayashi, T., Hayasaka, A., Kadono, S., Miyazaki, T., Haraya, K., Sekimori, Y., Kojima, T., Nabuchi, Y., Aso, Y., Kawabe, Y., and Hattori, K. (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol., 28 (11), 1203-1207.
111. Bumbaca, D., Boswell, C.A., Fielder, P.J., and Khawli, L.A. (2012) Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J., 14 (3), 554-558.
112. Boswell, C.A., Tesar, D.B., Mukhyala, K., Theil, F.P., Fielder, P.J., and Khawli, L.A. (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug. Chem., 21 (12), 2153-2163.
113. Lazar, G.A. and Desjarlais, J.R. (2009) Engineering the antibody Fc region for optimal effector function, in Therapeutic Monoclonal Antibodies (ed. Z. An), John Wiley & Sons, Inc., Hoboken, NJ, pp. 349-370.
114. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010) Complement: a key system for immune surveillance and homeostasis. Nat. Immunol., 11 (9), 785-797.
115. Desjarlais, J.R., Lazar, G.A., Zhukovsky, E.A., and Chu, S.Y. (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today, 12 (21-22), 898-910.
116. Gelderman, K.A., Tomlinson, S., Ross, G.D., and Gorter, A. (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol., 25 (3), 158-164.
117. Bruhns, P., Iannascoli, B., England, P., Mancardi, D.A., Fernandez, N., Jorieux, S., and Daeron, M. (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood, 113 (16), 3716-3725.
118. Lux, A. and Nimmerjahn, F. (2012) Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol., 33 (1), 4-8.
119. Selenko, N., Majdic, O., Jager, U., Sillaber, C., Stockl, J., and Knapp, W. (2002) Crosspriming of cytotoxic Tcells promoted by apoptosis-inducing tumor cell reactive antibodies? J. Clin. Immunol., 22 (3), 124-130.
120. van Sorge, N.M., van der Pol, W.L., and van de Winkel, J.G. (2003) FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens, 61 (3), 189-202.
121. Karassa, F.B., Trikalinos, T.A., and Ioannidis, J.P. (2004) The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed. Pharmacother., 58 (5), 286-291.
122. Sanders, L.A., Feldman, R.G., Voorhorst-Ogink, M.M., de Haas, M., Rijkers, G.T., Capel, P.J., Zegers, B.J., and van de Winkel, J.G. (1995) Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect. Immun., 63 (1), 73-81.
123. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., and Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99 (3), 754-758.
124. Treon, S.P., Hansen, M., Branagan, A.R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S.R., Touroutoglou, N., Turnbull, B., Anderson, K.C., Maloney, D.G., and Fox, E.A. (2005) Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J. Clin. Oncol., 23 (3), 474-481.
125. Kim, D.H., Jung, H.D., Kim, J.G., Lee, J.J., Yang, D.H., Park, Y.H., Do, Y.R., Shin, H.J., Kim, M.K., Hyun, M.S., and Sohn, S.K. (2006) FCGR3A gene polymorphisms may correlate with response to frontline RCHOP therapy for diffuse large B-cell lymphoma. Blood, 108 (8), 2720-2725.
126. Zhang, W., Wang, X., Li, J., Duan, M.H., and Zhou, D.B. (2010) Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin. Med. J. (Engl.), 123 (2), 198-202.
127. Mitrovic, Z., Aurer, I., Radman, I., Ajdukovic, R., Sertic, J., and Labar, B. (2007) FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica, 92 (7), 998-999.
128. Farag, S.S., Flinn, I.W., Modali, R., Lehman, T.A., Young, D., and Byrd, J.C. (2004) Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood, 103 (4), 1472-1474.
129. Dornan, D., Spleiss, O., Yeh, R.F., Duchateau-Nguyen, G., Dufour, A., Zhi, J., Robak, T., Moiseev, S.I., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Rossiev, V.A., Bence-Bruckler, I., Geisler, C.H., Montillo, M., Wenger, M.K., and Weisser, M. (2010) Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood, 116 (20), 4212-4222.
130. Cheung, N.K., Sowers, R., Vickers, A.J., Cheung, I.Y., Kushner, B.H., and Gorlick, R. (2006) FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J. Clin. Oncol., 24 (18), 2885-2890.
131. Cheung, I.Y., Hsu, K., and Cheung, N.K. (2012) Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colonystimulating factor. J. Clin. Oncol., 30 (4), 426-432.
132. Desjarlais, J.R. and Lazar, G.A. (2011) Modulation of antibody effector function. Exp. Cell Res., 317 (9), 1278-1285.
133. Beck, A. and Reichert, J.M. (2012) Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs, 4 (4), 419-425.
134. Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G., Parren, P.W., and Taylor, R.P. (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol., 183 (1), 749-758.
135. Han, Y., Kozel, T.R., Zhang, M.X., MacGill, R.S., Carroll, M.C., and Cutler, J.E. (2001) Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol., 167 (3), 1550-1557
136. Alduaij, W. and Illidge, T.M. (2011) The future of anti-CD20 monoclonal antibodies: are we making progress? Blood, 117 (11), 2993-3001.
137. Wang, S.Y., Racila, E., Taylor, R.P., and Weiner, G.J. (2008) NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood, 111 (3), 1456-1463.
138. Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., and Niwa, R. (2008) Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res., 68 (10), 3863-3872.
139. O'Brien, S. and Osterborg, A. (2010) Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk., 10 (5), 361-368.
140. Nimmerjahn, F. and Ravetch, J.V. (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science, 310 (5753), 1510-1512.
141. Richards, J.O., Karki, S., Lazar, G.A., Chen, H., Dang, W., and Desjarlais, J.R. (2008) Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther., 7 (8), 2517-2527.
142. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med., 6 (4), 443-446.
143. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., and Tedder, T.F. (2006) Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med., 203 (3), 743-753.
144. Dhodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E., Koenig, S., Steinman, R.M., Ravetch, J.V., and Dhodapkar, M.V. (2005) Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA, 102 (8), 2910-2915.
145. Smith, K.G. and Clatworthy, M.R. (2010) FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol., 10 (5), 328-343.
146. Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V., and Young, J.W. (2005) Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest., 115 (10), 2914-2923.
147. Lazar, G.A., Dang, W., Karki, S., Vafa, O., Peng, J.S., Hyun, L., Chan, C., Chung, H.S., Eivazi, A., Yoder, S.C., Vielmetter, J., Carmichael, D.F., Hayes, R.J., and Dahiyat, B.I. (2006) Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA, 103 (11), 4005-4010.
148. Horton, H.M., Bernett, M.J., Pong, E., Peipp, M., Karki, S., Chu, S.Y., Richards, J.O., Vostiar, I., Joyce, P.F., Repp, R., Desjarlais, J.R., and Zhukovsky, E.A. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res., 68 (19), 8049-8057.
149. Zalevsky, J., Leung, I.W., Karki, S., Chu, S.Y., Zhukovsky, E.A., Desjarlais, J.R., Carmichael, D.F., and Lawrence, C.E. (2009) The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood, 113 (16), 3735-3743.
150. Bruckheimer, E.M., Fazenbaker, C.A., Gallagher, S., Mulgrew, K., Fuhrmann, S., Coffman, K.T., Walsh, W., Ready, S., Cook, K., Damschroder, M., Kinch, M., Kiener, P.A., Woods, R., Gao, C., Dall'Acqua, W., Wu, H., and Coats, S. (2009) Antibodydependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia, 11 (6), 509-517.
151. Moore, G.L., Chen, H., Karki, S., and Lazar, G.A. (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs, 2 (2), 181-189.
152. Allan, B., Jiang, W., Tang, Y., and Watkins, J.D. (2010) Variant Fc regions. US Patent 7,740,847 (to Applied Molecular Evolution, Inc.).
153. Watkins, J.D. and Allan, B. (2004) Fc region variants. WO 2004/074455 A2.
154. Stavenhagen, J.B., Gorlatov, S., Tuaillon, N., Rankin, C.T., Li, H., Burke, S., Huang, L., Vijh, S., Johnson, S., Bonvini, E., and Koenig, S. (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via lowaffinity activating Fcgamma receptors. Cancer Res., 67 (18), 8882-8890.
155. Idusogie, E.E., Wong, P.Y., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., and Mulkerrin, M.G. (2001) Engineered antibodies with increased activity to recruit complement. J. Immunol., 166 (4), 2571-2575.
156. Stewart, R., Thom, G., Levens, M., Guler-Gane, G., Holgate, R., Rudd, P.M., Webster, C., Jermutus, L., and Lund, J. (2011) A variant human IgG1-Fc mediates improved ADCC. Protein Eng. Des. Sel., 24 (9), 671-678.
157. Sazinsky, S.L., Ott, R.G., Silver, N.W., Tidor, B., Ravetch, J.V., and Wittrup, K.D. (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. USA, 105 (51), 20167-20172.
158. Jung, S.T., Reddy, S.T., Kang, T.H., Borrok, M.J., Sandlie, I., Tucker, P.W., and Georgiou, G. (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. USA, 107 (2), 604-609.
159. Lu, Y., Vernes, J.M., Chiang, N., Ou, Q., Ding, J., Adams, C., Hong, K., Truong, B.T., Ng, D., Shen, A., Nakamura, G., Gong, Q., Presta, L.G., Beresini, M., Kelley, B., Lowman, H., Wong, W.L., and Meng, Y.G. (2011) Identification of IgG(1) variants with increased affinity to FcgammaRIIIa and unaltered affinity to FcgammaRI and FcRn: comparison of soluble receptorbased and cell-based binding assays. J. Immunol. Methods, 365 (1-2), 132-141.
160. Ferrara, C., Stuart, F., Sondermann, P., Brunker, P., and Umana, P. (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem., 281 (8), 5032-5036.
161. Chung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z.J., Shen, A., Vanderlaan, M., and Song, A. (2012) Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. mAbs, 4 (3), 326-340.
162. Mizushima, T., Yagi, H., Takemoto, E., Shibata-Koyama, M., Isoda, Y., Iida, S., Masuda, K., Satoh, M., and Kato, K. (2011) Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells, 16 (11), 1071-1080.
163. Listinsky, J.J., Siegal, G.P., and Listinsky, C.M. (2013) Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model. Anticancer Drugs, 24, 219-227.
164. Repp, R., Kellner, C., Muskulus, A., Staudinger, M., Nodehi, S.M., Glorius, P., Akramiene, D., Dechant, M., Fey, G.H., van Berkel, P.H., van de Winkel, J.G., Parren, P.W., Valerius, T., Gramatzki, M., and Peipp, M. (2011) Combined Fcprotein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. Methods, 373 (1-2), 67-78.
165. Dall'Acqua, W.F., Cook, K.E., Damschroder, M.M., Woods, R.M., and Wu, H. (2006) Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol., 177 (2), 1129-1138.
166. Alegre, M.L., Peterson, L.J., Xu, D., Sattar, H.A., Jeyarajah, D.R., Kowalkowski, K., Thistlethwaite, J.R., Zivin, R.A., Jolliffe, L., and Bluestone, J.A. (1994) A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation, 57 (11), 1537-1543.
167. Newman, R., Hariharan, K., Reff, M., Anderson, D.R., Braslawsky, G., Santoro, D., Hanna, N., Bugelski, P.J., Brigham-Burke, M., Crysler, C., Gagnon, R.C., Dal Monte, P., Doyle, M.L., Hensley, P.C., Reddy, M.P., Sweet, R.W., and Truneh, A. (2001) Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4þ Tcells in chimpanzees. Clin. Immunol., 98 (2), 164-174.
168. Hayden-Ledbetter, M.S., Cerveny, C.G., Espling, E., Brady, W.A., Grosmaire, L.S., Tan, P., Bader, R., Slater, S., Nilsson, C.A., Barone, D.S., Simon, A., Bradley, C., Thompson, P.A., Wahl, A.F., and Ledbetter, J.A. (2009) CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin. Cancer Res., 15 (8), 2739-2746.
169. Armour, K.L., Clark, M.R., Hadley, A.G., and Williamson, L.M. (1999) Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur. J. Immunol., 29 (8), 2613-2624.
170. An, Z., Forrest, G., Moore, R., Cukan, M., Haytko, P., Huang, L., Vitelli, S., Zhao, J.Z., Lu, P., Hua, J., Gibson, C.R., Harvey, B.R., Montgomery, D., Zaller, D., Wang, F., and Strohl, W. (2009) IgG2m4, an engineered antibody isotype with reduced Fc function. mAbs, 1 (6), 572-579.
171. Mueller, J.P., Evans, M.J., Mueller, E.E., Rollins, S., Rother, R.P., and Matis, L.A., Porcine cell interaction proteins. US Patent 9,615,575 (to Alexion Pharmaceuticals, Inc.).
172. van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W.K., Martinez-Martinez, P., Vermeulen, E., den Bleker, T.H., Wiegman, L., Vink, T., Aarden, L.A., De Baets, M.H., van de Winkel, J.G., Aalberse, R.C., and Parren, P.W. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science, 317 (5844), 1554-1557.
173. Reddy, M.P., Kinney, C.A., Chaikin, M.A., Payne, A., Fishman-Lobell, J., Tsui, P., Dal Monte, P.R., Doyle, M.L., Brigham-Burke, M.R., Anderson, D., Reff, M., Newman, R., Hanna, N., Sweet, R.W., and Truneh, A. (2000) Elimination of Fc receptordependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol., 164 (4), 1925-1933.
174. Xu, D., Alegre, M.L., Varga, S.S., Rothermel, A.L., Collins, A.M., Pulito, V.L., Hanna, L.S., Dolan, K.P., Parren, P.W., Bluestone, J.A., Jolliffe, L.K., and Zivin, R.A. (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol., 200 (1), 16-26.
175. Davis, P.M., Abraham, R., Xu, L., Nadler, S.G., and Suchard, S.J. (2007) Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol., 34 (11), 2204-2210.
176. McEarchern, J.A., Oflazoglu, E., Francisco, L., McDonagh, C.F., Gordon, K.A., Stone, I., Klussman, K., Turcott, E., van Rooijen, N., Carter, P., Grewal, I.S., Wahl, A.F., and Law, C.L. (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood, 109 (3), 1185-1192.
177. Oganesyan, V., Gao, C., Shirinian, L., Wu, H., and Dall'Acqua, W.F. (2008) Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr., 64 (Pt 6), 700-704.
178. Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S.D., Clark, M., and Waldmann, H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol., 23 (2), 403-411.
179. Walker, M.R., Lund, J., Thompson, K.M., and Jefferis, R. (1989) Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/ or Fc gamma RII receptors. Biochem. J., 259 (2), 347-353.
180. Cole, M.S., Stellrecht, K.E., Shi, J.D., Homola, M., Hsu, D.H., Anasetti, C., Vasquez, M., and Tso, J.Y. (1999) HuM291, a humanized anti-CD3 antibody, is immunosuppressive to Tcells while exhibiting reduced mitogenicity in vitro. Transplantation, 68 (4), 563-571.
181. Armour, K.L., Atherton, A., Williamson, L.M., and Clark, M.R. (2002) The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochem. Soc. Trans., 30 (4), 495-500.
182. Armour, K.L., van de Winkel, J.G., Williamson, L.M., and Clark, M.R. (2003) Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol. Immunol., 40 (9), 585-593.
183. Bell, L. and Rother, R.P. (2007) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement. US Patent Appl. 2007/006606 (to Alexion Pharmaceuticals, Inc.).
184. Hutchins, J.T., Kull, F.C., Jr., Bynum, J., Knick, V.C., Thurmond, L.M., and Ray, P. (1995) Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc. Natl. Acad. Sci. USA, 92 (26), 11980-11984.
185. Lund, J., Takahashi, N., Pound, J.D., Goodall, M., and Jefferis, R. (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol., 157 (11), 4963-4969.
186. Jung, S.T., Kang, T.H., Kelton, W., and Georgiou, G. (2011) Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr. Opin. Biotechnol., 22 (6), 858-867.
187. Friend, P.J., Hale, G., Chatenoud, L., Rebello, P., Bradley, J., Thiru, S., Phillips, J.M., and Waldmann, H. (1999) Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation, 68 (11), 1632-1637.
188. Woodle, E.S., Xu, D., Zivin, R.A., Auger, J., Charette, J., O'Laughlin, R., Peace, D., Jollife, L.K., Haverty, T., Bluestone, J.A., and Thistlethwaite, J.R., Jr. (1999) Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation, 68 (5), 608-616.
189. Liang, H., Chaparro-Riggers, J., Strop, P., Geng, T., Sutton, J.E., Tsai, D., Bai, L., Abdiche, Y., Dilley, J., Yu, J., Wu, S., Chin, S.M., Lee, N.A., Rossi, A., Lin, J.C., Rajpal, A., Pons, J., and Shelton, D.L. (2012) Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther., 340 (2), 228-236.
190. Glantschnig, H., Hampton, R.A., Lu, P., Zhao, J.Z., Vitelli, S., Huang, L., Haytko, P., Cusick, T., Ireland, C., Jarantow, S.W., Ernst, R., Wei, N., Nantermet, P., Scott, K.R., Fisher, J.E., Talamo, F., Orsatti, L., Reszka, A.A., Sandhu, P., Kimmel, D., Flores, O., Strohl, W., An, Z., and Wang, F. (2010) Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bonemass in vivo. J. Biol. Chem., 285 (51), 40135-40147.
191. Strohl, W.R. (2009) Optimization of Fcmediated effector functions of monoclonal antibodies. Curr. Opin. Biotechnol., 20 (6), 685-691.
192. Bostrom, J., Yu, S.F., Kan, D., Appleton, B.A., Lee, C.V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., and Fuh, G. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science, 323 (5921), 1610-1614.
193. Doppalapudi, V.R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N.J., Shields, M.J., Parish, M., Murphy, R.E., Del Rosario, J., Oates, B.D., Lai, J.Y., Matin, M.J., Ainekulu, Z., Bhat, A., Bradshaw, C.W., Woodnutt, G., Lerner, R.A., and Lappe, R.W. (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. USA, 107 (52), 22611-22616.
194. Coloma, M.J. and Morrison, S.L. (1997) Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol., 15 (2), 159-163.
195. Orcutt, K.D., Ackerman, M.E., Cieslewicz, M., Quiroz, E., Slusarczyk, A.L., Frangioni, J.V., and Wittrup, K.D. (2010) A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel., 23 (4), 221-228.
196. Klein, C., Sustmann, C., Thomas, M., Stubenrauch, K., Croasdale, R., Schanzer, J., Brinkmann, U., Kettenberger, H., Regula, J.T., and Schaefer, W. (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs, 4 (6), 653-663.
197. Kontermann, R. (2012) Dual targeting strategies with bispecific antibodies. mAbs, 4 (2), 182-197.
198. Carter, P. (2001) Bispecific human IgG by design. J. Immunol. Methods, 248 (1-2), 7-15.
199. Strop, P., Ho, W.H., Boustany, L.M., Abdiche, Y.N., Lindquist, K.C., Farias, S.E., Rickert, M., Appah, C.T., Pascua, E., Radcliffe, T., Sutton, J., Chaparro-Riggers, J., Chen, W., Casas, M.G., Chin, S.M., Wong, O.K., Liu, S.H., Vergara, G., Shelton, D., Rajpal, A., and Pons, J. (2012) Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol., 420 (3), 204-219.
200. Lindhofer, H., Mocikat, R., Steipe, B., and Thierfelder, S. (1995) Preferential speciesrestricted heavy/light chain pairing in rat/ mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol., 155 (1), 219-225.
201. Igawa, T. and Tsunoda, H. (2006) Process for production of polypeptide by regulation of assembly. PCT/JP2006/306803 (to Chugai Pharmaceutical Co. Ltd.).
202. Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S.B., Born, T., Retter, M., Manchulenko, K., Sweet, H., Foltz, I.N., Wittekind, M., and Yan, W. (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem., 285 (25), 19637-19646.
203. Dong, J., Demarest, S.J., Sereno, A., Tamraz, S., Langley, E., Doern, A., Snipas, T., Perron, K., Joseph, I., Glaser, S.M., Ho, S.N., Reff, M.E., and Hariharan, K. (2010) Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol. Cancer Ther., 9 (9), 2593-2604.
204. Schaefer, W., Regula, J.T., Bahner, M., Schanzer, J., Croasdale, R., Durr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., Schwaiger, M., Stubenrauch, K.G., Sustmann, C., Thomas, M., Scheuer, W., and Klein, C. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA, 108 (27), 11187-11192.
205. Mabry, R., Gilbertson, D.G., Frank, A., Vu, T., Ardourel, D., Ostrander, C., Stevens, B., Julien, S., Franke, S., Meengs, B., Brody, J., Presnell, S., Hamacher, N.B., Lantry, M., Wolf, A., Bukowski, T., Rosler, R., Yen, C., Anderson-Haley, M., Brasel, K., Pan, Q., Franklin, H., Thompson, P., Dodds, M., Underwood, S., Peterson, S., Sivakumar, P.V., and Snavely, M. (2010) A dualtargeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. mAbs, 2 (1), 20-34.
206. Stish, B.J., Chen, H., Shu, Y., Panoskaltsis-Mortari, A., and Vallera, D.A. (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin. Cancer Res., 13 (10), 3058-3067.
207. Linke, R., Klein, A., Seimetz, D. (2010) Catumaxomab: clinical development and future directions. mAbs, 2 (2), 129-136.
208. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group, D'Amico, D.J., Masonson, H.N., Patel, M., Adamis, A.P., Cunningham, E.T., Jr., Guyer, D.R., and Katz, B. (2006) Pegaptanib sodium for neovascular agerelated macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology, 113 (6), 992-1001, e1006.
209. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L., and Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med., 363 (19), 1812-1821.
210. Doronina, S.O., Mendelsohn, B.A., Bovee, T.D., Cerveny, C.G., Alley, S.C., Meyer, D.L., Oflazoglu, E., Toki, B.E., Sanderson, R.J., Zabinski, R.F., Wahl, A.F., and Senter, P.D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem., 17 (1), 114-124.
211. Widdison, W.C., Wilhelm, S.D., Cavanagh, E.E., Whiteman, K.R., Leece, B.A., Kovtun, Y., Goldmacher, V.S., Xie, H., Steeves, R.M., Lutz, R.J., Zhao, R., Wang, L., Blattler, W.A., and Chari, R.V. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem., 49 (14), 4392-4408.
212. Adair, J.R., Howard, P.W., Hartley, J.A., Williams, D.G., and Chester, K.A. (2012) Antibody-drug conjugates-a perfect synergy. Expert Opin. Biol. Ther., 12 (9), 1191-1206.
213. Ducry, L. and Stump, B. (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem., 21 (1), 5-13.
214. Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., Blattler, W.A., Lambert, J.M., Chari, R.V., Lutz, R.J., Wong, W.L., Jacobson, F.S., Koeppen, H., Schwall, R.H., Kenkare-Mitra, S.R., Spencer, S.D., and Sliwkowski, M.X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res., 68 (22), 9280-9290.
215. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., and Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res., 7 (6), 1490-1496.
216. Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M., Lenox, J., Cerveny, C.G., Kissler, K.M., Bernhardt, S.X., Kopcha, A.K., Zabinski, R.F., Meyer, D.L., and Francisco, J.A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res., 10 (20), 7063-7070.
217. Wang, L., Amphlett, G., Blattler, W.A., Lambert, J.M., and Zhang, W. (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci., 14 (9), 2436-2446.
218. Axup, J.Y., Bajjuri, K.M., Ritland, M., Hutchins, B.M., Kim, C.H., Kazane, S.A., Halder, R., Forsyth, J.S., Santidrian, A.F., Stafin, K., Lu, Y., Tran, H., Seller, A.J., Biroc, S.L., Szydlik, A., Pinkstaff, J.K., Tian, F., Sinha, S.C., Felding-Habermann, B., Smider, V.V., and Schultz, P.G. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA, 109 (40), 16101-16106.
219. Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., Chen, Y., Simpson, M., Tsai, S.P., Dennis, M.S., Lu, Y., Meng, Y.G., Ng, C., Yang, J., Lee, C.C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S.D., Lee Wong, W., Lowman, H.B., Vandlen, R., Sliwkowski, M.X., Scheller, R.H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol., 26 (8), 925-932.
220. Strop, P., Liu, S.H., Dorywalska, M., Delaria, K., Dushin, R., Tran, T., Ho, W.-H., Farias, S., Casas, M.G., Abdiche, Y., Zhou, D., Chandrasekaran, R., Samain, C., Loo, C., Rossi, A., Rickert, M., Krimm, S., Wong, T., Chin, S.M., Yu, J., Dilley, J., Chaparro-Riggers, J., Filzen, G., O'Donnell, C.J., Wang, F., Myers, J.S., Pons, J., Shelton, D.L., and Rajpal, A. (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody-drug conjugates. Chem. Biol., 20 (2), 161-167.
221. Trail, P.A., Willner, D., Lasch, S.J., Henderson, A.J., Hofstead, S., Casazza, A.M., Firestone, R.A., Hellstrom, I., and Hellstrom, K.E. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science, 261 (5118), 212-215.
222. Tolcher, A.W., Sugarman, S., Gelmon, K.A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., and Slichenmyer, W. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol., 17 (2), 478-484.
223. Dubowchik, G.M., Firestone, R.A., Padilla, L., Willner, D., Hofstead, S.J., Mosure, K., Knipe, J.O., Lasch, S.J., and Trail, P.A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem., 13 (4), 855-869.
224. Sorokin, P. (2000) Mylotarg approved for patients with CD33þ acute myeloid leukemia. Clin. J. Oncol. Nurs., 4 (6), 279-280.
225. Petersdorf, S., Kopecky, K., Stuart, R.K., Larson, R.A., Nevill, T.J., Stenke, L., Slovak, M.L., Tallman, M.S., Willman, C.L., Erba, H., and Appelbaum, F.R. (2009) Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. 51st ASH Annual Meeting and Exposition, New Orleans, LA.
226. Gerber, H.P., Koehn, F.E., and Abraham, R.T. (2013) The antibody-drug conjugate: an enabling modality for natural productbased cancer therapeutics. Nat. Prod. Rep., 30 (5), 625-639.